Ozempic and vision loss: NAION is real but very rare

Key takeaways

• NAION (nonarteritic anterior ischemic optic neuropathy) is a small stroke of the optic nerve that causes sudden, usually painless vision loss in one eye. It is uncommon to start with, about 2 to 10 cases per 100,000 people over 50 each year .
• Semaglutide is linked to roughly double that risk. A Danish study of 424,152 people with type 2 diabetes found about a two-fold increase (hazard ratio 2.19), and a 2026 US study of 482,912 matched pairs found an 85% increase overall (hazard ratio 1.85), with semaglutide specifically closer to 2.8-fold .
• In absolute terms the extra risk is small. Europe's medicines regulator put it at about one extra NAION case for every 10,000 person-years of treatment and classed it very rare, meaning up to 1 in 10,000 people .
• The scariest early numbers came from one eye clinic. The 2024 study that set off the alarm reported much larger risks, 4-fold to 8-fold, but in patients already attending a neuro-ophthalmology practice, so those figures are not the odds for an average user .
• The warning sign is sudden vision change in one eye. If your sight drops or blurs in one eye, especially on waking, get it checked right away. If NAION is confirmed, the guidance is to stop semaglutide, because vision loss from NAION is usually permanent .

Skip to:

• How worried should you be, in plain numbers
• What NAION is, and why it tends to be permanent
• What the studies actually found
• What regulators concluded in 2025
• Who is more likely to get it
• The honest bottom line

How worried should you be, in plain numbers

Somewhere around late 2024 the phrase 'Ozempic can cause blindness' went everywhere, usually attached to one study. The numbers in it were real, but they came from a narrow slice of patients, and the bigger studies that followed landed a lot lower. Line them up side by side and the story gets clearer.

What NAION is, and why it tends to be permanent

NAION stands for nonarteritic anterior ischemic optic neuropathy, which is a mouthful for a simple idea: the optic nerve loses enough blood flow that part of it is damaged. Think of it as a stroke of the optic nerve. It is the most common cause of optic-nerve vision loss in adults over 50 .

It usually shows up as sudden, painless vision loss in one eye, and people often notice it the first moment they wake up . There is no pain, no warning ache, just a chunk of vision gone or a curtain over part of the field.

It mostly does not come back. For most people, visual acuity does not change much after the event settles. About 30% regain some vision at two years, about 20% get worse, and the rest stay where they landed. There is no universally accepted treatment that reverses it . That permanence is why a rare risk still gets attention, and why the warning sign is worth knowing even though spotting it will not restore sight that is already lost.

NAION is also uncommon to begin with. In the US it runs about 2.3 to 10.3 cases per 100,000 people aged 50 or older per year . That is the baseline the semaglutide studies are doubling. Even doubled, it stays rare.

What the studies actually found

The alarm started in August 2024 with a study in JAMA Ophthalmology by Hathaway and colleagues. They found semaglutide linked to a 4.28-fold higher risk of NAION in people with type 2 diabetes and a 7.64-fold higher risk in people who were overweight or had obesity .

Those numbers are alarming until you read who was in the study. It was a single center (a Boston neuro-ophthalmology practice), it was looking back at records, and the patients were people already coming in for eye problems. That design is good at flagging that an association might exist. It is bad at telling you the odds for a typical person picking up a pen at the pharmacy, because the group it studied is not typical .

The bigger, broader studies that came next are the ones to weight. A Danish nationwide study followed 424,152 people with type 2 diabetes and found once-weekly semaglutide roughly doubled the five-year risk of NAION, a hazard ratio of 2.19. In real cases that was 0.228 per 1,000 person-years on semaglutide versus 0.093 without it .

A 2026 US study went wider still, comparing 482,912 matched pairs who started a GLP-1 drug versus an SGLT2 diabetes drug. GLP-1 use came with an 85% higher risk overall (hazard ratio 1.85), and semaglutide specifically ran about 2.8-fold. The extra cases worked out to about 0.29 per 1,000 person-years, and the authors said plainly that the absolute increase was small .

One honest caveat runs through all of it. These are observational studies, so they show an association, not proof the drug is the cause, and nobody has pinned down a mechanism. Europe's regulator noted that the clinical-trial data showed only a slightly higher risk, while the large epidemiology studies showed about double . The exact size is not fully settled. The direction (a real, small, roughly doubled risk) was consistent enough that regulators acted on it.

What regulators concluded in 2025

In mid-2025 the regulators moved. On 6 June 2025 the European Medicines Agency's safety committee (the PRAC) concluded that NAION counts as a very rare side effect of semaglutide, covering Ozempic, Rybelsus, and Wegovy, and recommended the product information be updated to list it at a frequency of very rare, meaning up to 1 in 10,000 people. They put the effect at about a two-fold increase in risk, which works out to roughly one extra NAION case for every 10,000 person-years of treatment .

The World Health Organization echoed it on 27 June 2025, noting the same very-rare classification and that its own advisory committee recommended adding NAION to the drug's risk management plan. The patient-facing guidance from both is the same and worth repeating: if you suddenly lose vision or your eyesight rapidly gets worse while on treatment, contact a doctor without delay, and if NAION is confirmed, treatment should be stopped .

Who is more likely to get it

NAION does not hit at random. The biggest structural risk is something called a 'disc at risk', an optic nerve head that is small and crowded, with a cup-to-disc ratio around 0.2 or less. You cannot feel it, but an eye doctor can see it on an exam .

The other strong risk factors are the vascular ones: high blood pressure, high cholesterol, diabetes, cardiovascular or cerebrovascular disease, and obstructive sleep apnea . Notice how much that list overlaps with the reasons people are on semaglutide in the first place. Part of why NAION shows up in this population is the population itself.

• A 'disc at risk' (small, crowded optic nerve), which an eye exam can spot .
• Sleep apnea, high blood pressure, high cholesterol, and diabetes .
• A prior NAION in one eye, which raises the stakes for the other eye and is worth flagging to whoever manages your care .

None of this is a reason to skip the drug. It is a reason to know where you sit. If you already have several of these, an eye check before or early into treatment is a reasonable, low-cost thing to have on record, and it gives you a baseline if anything changes later.

The honest bottom line

Semaglutide is linked to NAION, the link looks like roughly a doubling of risk, and NAION vision loss is usually permanent. All true, and all worth knowing. The headlines just left out the size. NAION is rare, so a doubling barely moves the absolute odds, which is why Europe's regulator and the WHO both file it under very rare .

For a rare, low-frequency risk, the move is not to quit over the headline. It is to keep one fact in your head the way you keep your dose math and your injection sites: sudden vision change in one eye means stop and get seen, fast. If you carry the vascular risk factors, an eye exam on record early is a cheap precaution. The same trade-off logic runs through the other GLP-1 side effects worth knowing, from Ozempic face to the gut and fatigue effects people report.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 6 entries, primary canon (NIH StatPearls, PubMed-indexed cohort studies, WHO) plus the EU medicines regulator, acknowledged inline. Last reviewed 2026-07-07.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.

Frequently asked questions

Does Ozempic cause blindness?

Semaglutide (Ozempic, Wegovy, Rybelsus) is linked to about double the risk of NAION, a rare condition where a small stroke of the optic nerve causes sudden vision loss in one eye. Because NAION is uncommon to begin with, the extra risk works out to roughly one case per 10,000 people treated for a year, and European regulators and the WHO classify it as a very rare side effect.

Is the vision loss from NAION permanent?

Usually, yes. For most people, vision does not change much after the event settles. About 30% regain some vision at two years and about 20% get worse, and there is no proven treatment that reverses it. That is why the risk gets attention even though it is rare.

What are the warning signs of NAION on semaglutide?

Sudden loss of vision or blurring in one eye, often first noticed on waking, and usually with no pain. If that happens, contact an eye doctor or urgent care without delay. Catching it does not reverse it, but it gets you a diagnosis, the decision on whether to stop the drug, and a check on the other eye.

Should I stop taking semaglutide because of this?

The vision risk on its own is small and is not, for most people, a reason to stop. The guidance from regulators is to stop semaglutide only if NAION is actually confirmed. If you carry vascular risk factors like sleep apnea, high blood pressure, or a family history of optic-nerve problems, an eye exam on record early is a reasonable precaution.